NovoSeven
Orphan Drug Cold Chain RequiredFDA Approved
Contents
Description
NovoSeven is a recombinant coagulation factor VIIa indicated for the treatment of bleeding episodes and for the prevention of bleeding in surgical procedures in patients with rare hemorrhagic disorder due to a coagulation factors defect. It works by initiating blood clotting.
Indications & Therapeutic Use
Hemophilia A or B with inhibitors, rare hemorrhagic disorder due to a coagulation factors defect, Acquired hemophilia
Linked Diseases:
Global Availability (4 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source NovoSeven — GNH India
4 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all NovoSeven products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
NovoSeven
| Generic Name | NovoSeven |
| Brands | 1 brand available |
| Active Ingredient | Eptacog beta (activated) |
| Drug Class | Hemophilia A or B with inhibitors |
| Manufacturer | Novo Nordisk |
| Dosage Forms | Powder and solvent for solution for injection |
| Medical Code | B02BD07 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00344332 |
| Countries | 4 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations5 Validated Nodes